Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Pyrophyte Acquisition Corp. II Signs $600M M&A Deal with Sakuu Corporation
Pyrophyte Acquisition Corp. II (NYSE: PAII) entered into a definitive business combination agreement to acquire Sakuu Corporation, a Silicon Valley-based energy storage manufacturing technology company. The transaction implies a pre-money equity value of $600 million for Sakuu, with the combined company expected to list on the NYSE under the ticker 'SAKU'.
Value
$600M
Counterparty
Sakuu Corporation
“Kavian technology is not only the world’s first additive manufacturing solution to dry print high-performance battery electrodes at scale; it can also dry print supercapacitor electrodes customized for the growing power needs of AI data centers. It is the only known solution for producing heavily in-demand energy products that can be custom-printed rapidly, sustainably, and cost-effectively.”
Robert Bagheri, Sakuu Founder and Chief Executive Officer
OpenWorld signed a non-binding term sheet with Meridian to establish a $1 billion tokenized financing program for a distributed AI computing network powered by solar energy and Tesla Powerwall batteries. OpenWorld will serve as the structuring agent and operator for the network, which aims to deploy compute nodes across 10,000 homes and commercial sites starting in Q4 2026.
TheRealReal $175M Debt Financing with Fortress Credit Corp.
The RealReal entered into a new credit agreement with Fortress Credit Corp. providing for a $150 million senior secured term loan and a $25 million revolving credit facility. The proceeds will be used to redeem the company's existing 2029 Senior Secured Notes, extending its debt maturity profile to 2033 and reducing annual interest expense by approximately $4 million.
Dankon Corporation reported revenues of $54,694 and a net loss of $5,710 for the six months ended August 31, 2026. The company faces a working capital deficit of $101,970 and relies on loans from its CEO, leading to substantial doubt about its ability to continue as a going concern.
ASP Isotopes Partnership with Nuclear Energy Corporation of South Africa SOC Limited
ASP Isotopes' subsidiary Quantum Leap Energy (QLE) signed a binding Heads of Agreement with Necsa to form a joint venture (80% QLE / 20% Necsa) to develop and operate a commercial-scale HALEU production facility in South Africa. The venture will utilize QLE's enrichment technology and Necsa's Pelindaba site infrastructure, supported by existing offtake agreements with TerraPower.
Counterparty
Nuclear Energy Corporation of South Africa SOC Limited (Necsa)
For the quarter ended September 30, 2026, Marsh & McLennan reported revenue of $6.86 billion, an 8% increase over the prior year, though net income attributable to the Company grew more modestly to $808 million. For the nine-month period, operating income decreased slightly to $4.87 billion from $5.00 billion, primarily due to higher operating expenses and a significant increase in the purchase of treasury shares totaling $2.02 billion.
CCC Intelligent Solutions Holdings Signs $6.1B M&A Deal with GTCR and Elliott Investment Management L.P.
CCC Intelligent Solutions Holdings Inc. has entered into a definitive agreement to be acquired by a consortium led by GTCR and Elliott Investment Management in an all-cash transaction valued at approximately $6.1 billion. Stockholders will receive $7.75 per share in cash, representing a 44% premium to the company's unaffected closing price. The deal is expected to close in the first quarter of 2027, at which point CCC will become a privately held company.
Marsh & McLennan Companies (now branded as Marsh) reported third quarter 2026 revenue of $6.9 billion, an 8% increase year-over-year. The company achieved 5% underlying revenue growth and a 10% increase in adjusted EPS to $2.03, while also completing a major brand transition and executing its Thrive program.
Term
Q3 2026
“Marsh delivered a strong third quarter, generating 5% underlying revenue growth and double-digit EPS growth. We also made significant progress in executing our Thrive program and successfully completed our brand transition.”
John Doyle, President and CEO
“These results reflect the strength of our market position, the value we deliver to clients, and the commitment of our colleagues around the world.”
FMC Corporation updated its Q3 2026 guidance, significantly lowering expectations due to $625 million to $675 million in charges related to commercial actions. These actions include lowering prices for products held by channel customers in key markets and modifying the U.S. selling and pricing model to accelerate product movement and return to growth.
Commercial Metals Company reported fourth quarter fiscal 2026 net earnings of $212.5 million, or $1.91 per diluted share, representing a 40% increase year-over-year. Results were driven by strong growth in the North America Steel Group and the integration of acquired precast operations, with consolidated core EBITDA reaching $393.7 million.
Term
Q4 2026
“Fiscal 2026 marked a transformational step forward for CMC. We continued to build organizational strength and enhance margin durability in our early-stage construction portfolio through our precast acquisitions, our successful TAG program, and our key growth investments, including our West Virginia micro mill.”
Peter Matt, President and Chief Executive Officer
“With backlogs near record levels, a differentiated portfolio of solutions, and multiple value creation levers, we are well-positioned to deliver strong financial results and achieve our strategic goals in fiscal 2027.”
Ocugen, Inc. filed a formal investor presentation deck for October 2026 detailing its strategic pipeline and clinical milestones. The company is targeting three Biologics License Applications (BLAs) by 2028 for its gene therapy candidates OCU400, OCU410, and OCU410ST, which address major blindness diseases.
SurgePays, Inc. filed an updated corporate investor presentation dated October 2026 to its website and as an exhibit to its 8-K. The presentation provides summary information regarding the company's business operations and corporate profile for investors.
Bank7 Corp. reported Q3 2026 net income of $10.20 million, a 22.25% increase over the prior quarter, driven by loan growth and strong net interest margins. The company also announced that its acquisition of Century Financial is expected to close on November 1, 2026, following shareholder and regulatory approvals.
Term
Q3 2026
“We are pleased with another quarter of strong core results, including growth in the loan book despite significant payoffs, while also maintaining a healthy pipeline of new loans. The Company continues to benefit from high capital levels, robust liquidity, a strong net interest margin, and excellent credit quality, supported by our properly matched balance sheet and our position in dynamic markets.”
Thomas L. Travis, President and CEO of the Company
“Regarding the Century merger, we are pleased to report that in addition to receiving all regulatory approvals, the Century Financial shareholders have approved the merger, which is expected to close on November 1, 2026. The merger will extend the franchise into New Mexico and will allow the Company’s proven model to leverage Century’s core deposits to provide a highly accretive impact on earnings.”
Thomas L. Travis, President and CEO of the Company
Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.
Valion Bio's subsidiary, Velocity Bioworks, successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, achieving a milestone in their partnership. The evaluation demonstrated that NMR measurements can track microbial growth in real-time, supporting the development of non-invasive bioprocess monitoring for biologics manufacturing.
ManpowerGroup reported Q3 2026 revenues of $4.8 billion, a 4% increase year-over-year, driven by strength in its Manpower brand and improving trends in Experis. Net earnings rose to $34.1 million, or $0.71 per diluted share, compared to $18.0 million in the prior year period. The company also announced a leadership transition with Becky Frankiewicz set to become CEO on January 1, 2027.
Term
Q3 2026
“We delivered another quarter of consistent performance and strong execution as momentum continues across the organization. Our Manpower brand continues to lead the way, with notable share gains in the U.S. Our Experis and Talent Solutions brands experienced sequential revenue trend improvement which is encouraging. Our performance to date reinforces our confidence that 2026 is an inflection point for the business. At the same time, we continue to advance our transformation, expanding implementation beyond the U.S. and driving growth across our brands and regions while remaining on track to deliver on our cost savings target. Looking ahead, the combination of improving demand, strong execution, and continued progress on our transformation positions ManpowerGroup to drive sustainable, profitable growth.”
Allstate announced estimated catastrophe losses for September 2026 of $220 million ($173 million after-tax). Total catastrophe losses for the third quarter of 2026 reached $1.65 billion ($1.30 billion after-tax).
ManpowerGroup has appointed Becky Frankiewicz as Chief Executive Officer and a member of the Board, effective January 1, 2027. She succeeds Jonas Prising, who will retire as CEO and transition to the role of Executive Chair of the Board. Frankiewicz, who currently serves as President and Chief Strategy Officer, will receive an increased base salary of $1.15 million and a 2027 target long-term incentive opportunity of $7.5 million.
First Horizon reported a third-quarter net loss of $94 million, primarily due to a $347 million after-tax notable item related to the strategic reclassification of $4.5 billion in lower-yielding consumer mortgages to held-for-sale. Excluding these items, adjusted EPS was $0.53, supported by a $1.3 billion increase in average client deposits and disciplined expense management.
Term
Q3 2026
“This quarter’s results are a testament to our disciplined approach and clear strategic priorities. Average client deposit balances increased $1.3 billion in the quarter, and we continue to focus on growing and maintaining full client relationships and deploying capital where it best serves long-term value creation. Looking ahead, we remain committed to executing our strategy and delivering sustainable growth and value for our clients, associates, and shareholders.”
Bryan Jordan, Chairman, President and CEO of First Horizon Corporation
Gibraltar Industries Divestiture to GCP Applied Technologies Inc. for $208M
Gibraltar Industries has entered into a definitive agreement to sell its Infrastructure business, The D.S. Brown Company, to GCP Applied Technologies (an affiliate of Saint-Gobain) for $208 million in cash. The divestiture is part of a strategic plan to simplify the company's portfolio and focus on building products and structures, with proceeds intended for debt reduction.
Value
$208M
Counterparty
GCP Applied Technologies Inc. (Saint-Gobain Corporation)
Plug Power provided a preliminary Q3 2026 business update, reporting expected revenue growth of over 10% year-over-year and a record low net cash usage of approximately $28 million. The company reaffirmed its full-year 2026 revenue growth guidance of 15% to 16% and noted it did not raise any capital through its ATM program during the quarter.
Aquestive Therapeutics announced that the FDA has accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film as complete and assigned a PDUFA goal date of March 16, 2027. The resubmission follows positive results from studies designed to address a prior Complete Response Letter, positioning Anaphylm to potentially become the first oral rescue medication for severe allergic reactions.
Oaktree Acquisition Corp. III Life Sciences Other 8-K Filing
Oaktree Acquisition Corp. III Life Sciences announced preliminary redemption results ahead of its shareholder meeting to extend its business combination deadline, with 13,326,977 Class A shares tendered for redemption. Additionally, the company's sponsor intends to convert 4,798,758 Class B ordinary shares into Class A ordinary shares on a one-for-one basis prior to the extension's effectiveness.
Kimberly-Clark reported preliminary third quarter 2026 financial results, including net sales of $4.13 billion and diluted EPS of $5.37. The company reaffirmed its full-year 2026 outlook, expecting adjusted operating profit to grow mid-single digits on a constant-currency basis despite social media disruptions in China.
MGP Ingredients, Inc. announced it is rebranding as Sempreon, Inc., effective November 2, 2026. The company will also change its Nasdaq ticker symbol from MGPI to CASK to reflect its evolution across branded spirits, distilling, and ingredient solutions.
Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.
Cronos Group completed the acquisition of CanAdelaar B.V., a licensed cannabis grower in the Dutch Controlled Cannabis Supply Chain Experiment, for a base purchase price of €57.5 million plus earnouts. The deal establishes Cronos' European platform in the Netherlands' adult-use cannabis pilot program, with the buyer deducting €12.5 million from the initial price to cover a potential environmental penalty.
J.W. Mays, Inc. promoted Kevin J. Guptar to the roles of Chief Financial Officer and Treasurer, effective October 13, 2026. Mr. Guptar succeeds Ward Lyke, Jr., who retired on September 25, 2026, and will receive an annual base salary of $232,000 plus a discretionary bonus.
Esquire Financial Holdings M&A Deal with Signature Bancorporation, Inc.
Esquire Financial Holdings, Inc. completed its merger with Signature Bancorporation, Inc. on August 1, 2026, following a definitive agreement signed in March 2026. This filing serves as an amendment to provide required pro forma financial information showing the combined entity's financial condition as of March 31, 2026.
Tonix Pharmaceuticals provided preliminary operating results for the third quarter ended September 30, 2026, estimating net revenue for TONMYA between $14.0 million and $15.0 million. The company also reported an estimated cash and cash equivalents balance of approximately $162.8 million as of quarter-end.